PortfoliosLab logoPortfoliosLab logo
XPH vs. LFSC
Performance
Return for Risk
Dividends
Drawdowns
Volatility

Performance

XPH vs. LFSC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in SPDR S&P Pharmaceuticals ETF (XPH) and F/m Emerald Life Sciences Innovation ETF (LFSC). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

XPH vs. LFSC - Yearly Performance Comparison


2026 (YTD)20252024
XPH
SPDR S&P Pharmaceuticals ETF
-3.32%31.60%-6.21%
LFSC
F/m Emerald Life Sciences Innovation ETF
-4.45%56.54%-6.02%

Returns By Period

In the year-to-date period, XPH achieves a -3.32% return, which is significantly higher than LFSC's -4.45% return.


XPH

1D
5.32%
1M
-5.56%
YTD
-3.32%
6M
13.19%
1Y
24.45%
3Y*
11.04%
5Y*
2.79%
10Y*
3.82%

LFSC

1D
6.16%
1M
-3.82%
YTD
-4.45%
6M
17.66%
1Y
55.83%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


XPH vs. LFSC - Expense Ratio Comparison

XPH has a 0.35% expense ratio, which is lower than LFSC's 0.54% expense ratio.


Return for Risk

XPH vs. LFSC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XPH
XPH Risk / Return Rank: 5959
Overall Rank
XPH Sharpe Ratio Rank: 5959
Sharpe Ratio Rank
XPH Sortino Ratio Rank: 5959
Sortino Ratio Rank
XPH Omega Ratio Rank: 5050
Omega Ratio Rank
XPH Calmar Ratio Rank: 7171
Calmar Ratio Rank
XPH Martin Ratio Rank: 5858
Martin Ratio Rank

LFSC
LFSC Risk / Return Rank: 8686
Overall Rank
LFSC Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
LFSC Sortino Ratio Rank: 9090
Sortino Ratio Rank
LFSC Omega Ratio Rank: 8282
Omega Ratio Rank
LFSC Calmar Ratio Rank: 9191
Calmar Ratio Rank
LFSC Martin Ratio Rank: 7979
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XPH vs. LFSC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and F/m Emerald Life Sciences Innovation ETF (LFSC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


XPHLFSCDifference

Sharpe ratio

Return per unit of total volatility

1.00

1.93

-0.92

Sortino ratio

Return per unit of downside risk

1.47

2.65

-1.18

Omega ratio

Gain probability vs. loss probability

1.19

1.33

-0.14

Calmar ratio

Return relative to maximum drawdown

1.77

3.20

-1.43

Martin ratio

Return relative to average drawdown

5.52

8.96

-3.44

XPH vs. LFSC - Sharpe Ratio Comparison

The current XPH Sharpe Ratio is 1.00, which is lower than the LFSC Sharpe Ratio of 1.93. The chart below compares the historical Sharpe Ratios of XPH and LFSC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


XPHLFSCDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.00

1.93

-0.92

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.14

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.17

Sharpe Ratio (All Time)

Calculated using the full available price history

0.38

0.94

-0.57

Correlation

The correlation between XPH and LFSC is 0.78, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.


Dividends

XPH vs. LFSC - Dividend Comparison

XPH's dividend yield for the trailing twelve months is around 0.69%, while LFSC has not paid dividends to shareholders.


TTM20252024202320222021202020192018201720162015
XPH
SPDR S&P Pharmaceuticals ETF
0.69%0.83%1.58%1.28%1.64%0.95%0.47%0.64%0.65%0.67%0.63%7.15%
LFSC
F/m Emerald Life Sciences Innovation ETF
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

XPH vs. LFSC - Drawdown Comparison

The maximum XPH drawdown since its inception was -48.03%, which is greater than LFSC's maximum drawdown of -29.74%. Use the drawdown chart below to compare losses from any high point for XPH and LFSC.


Loading graphics...

Drawdown Indicators


XPHLFSCDifference

Max Drawdown

Largest peak-to-trough decline

-48.03%

-29.74%

-18.29%

Max Drawdown (1Y)

Largest decline over 1 year

-13.15%

-16.25%

+3.10%

Max Drawdown (5Y)

Largest decline over 5 years

-31.63%

Max Drawdown (10Y)

Largest decline over 10 years

-35.97%

Current Drawdown

Current decline from peak

-7.29%

-11.08%

+3.79%

Average Drawdown

Average peak-to-trough decline

-17.37%

-8.25%

-9.12%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.23%

5.80%

-0.57%

Volatility

XPH vs. LFSC - Volatility Comparison

The current volatility for SPDR S&P Pharmaceuticals ETF (XPH) is 9.49%, while F/m Emerald Life Sciences Innovation ETF (LFSC) has a volatility of 10.35%. This indicates that XPH experiences smaller price fluctuations and is considered to be less risky than LFSC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


XPHLFSCDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.49%

10.35%

-0.86%

Volatility (6M)

Calculated over the trailing 6-month period

16.38%

19.97%

-3.59%

Volatility (1Y)

Calculated over the trailing 1-year period

24.72%

29.24%

-4.52%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

20.56%

29.31%

-8.75%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.22%

29.31%

-7.09%